Epidemiology of Anti-JCV Antibody Prevalence in Multiple Sclerosis Patients: JEMS

Completed

• Conditions: disorder of the central nervous system; Multiple Sclerosis; 10007951

• Registration Number: NL-OMON34210
• Lead Sponsor: Biogen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 190

Inclusion Criteria

All candidates for this study must have the ability to understand the purpose of the study and
provide signed and dated informed consent.
All patients with a diagnosis of MS of any type, irrespective of their treatment, are eligible to
participate once.

Exclusion Criteria

All candidates not able to understand the purpose of the study and not able to provide signed and dated informed consent.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Prevalence of anti-JCV antibodies will be estimated as the number of patients<br /><br>with anti-JCV<br /><br>antibodies detected in serum divided by the total number of patients with a<br /><br>serum sample that<br /><br>was evaluated. Prevalence of anti-JCV antibodies will also be estimated by the<br /><br>criteria described<br /><br>in the objective of the study.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Not applicable</p><br>